Get the Stockscreener App
0.7359
2.00%
0.015
Invivyd Inc stock is traded at $0.7359, with a volume of 1.30M.
It is up +2.00% in the last 24 hours and down -0.97% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$0.7209
Open:
$0.71
24h Volume:
1.30M
Relative Volume:
0.30
Market Cap:
$216.85M
Revenue:
$55.87M
Net Income/Loss:
$-77.60M
P/E Ratio:
-2.0631
EPS:
-0.3567
Net Cash Flow:
$-79.46M
1W Performance:
+9.24%
1M Performance:
-0.97%
6M Performance:
-52.56%
1Y Performance:
+3.99%
1-Day Range:
$0.682
$0.7496
1-Week Range:
$0.66
$0.7496
52-Week Range:
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.7357 | 212.49M | 55.87M | -77.60M | -79.46M | -0.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
516.25 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.82 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.77 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.15 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.23 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
Invivyd (IVVD) sees 6.3% ownership reported by Perceptive Advisors group - Stock Titan
Invivyd (IVVD): BVF-led group discloses 29.6M shares, 9.99% beneficial stake - Stock Titan
Invivyd earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
Invivyd (NASDAQ:IVVD) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo! Finance Canada
Invivyd, Inc. Q2 2026: Revenue $14.29M, EPS $(0.14) — 10-Q Summary - TradingView
Invivyd (IVVD) widens loss, warns on going concern as cash falls to $160M - Stock Titan
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
BRIEF-Invivyd Q2 EPS USD -0.14 - TradingView
IVVD Q2'26 Earnings: revenue estimate is 14.40M USD - TradingView
Invivyd Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Moomoo
Invivyd, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Invivyd Inc (IVVD) Stock News Today - TradingKey
Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd (IVVD) Gains 7.27% to $0.61, Testing Key Resistance After Volatile SessionInverse ETF Flow - dars.gov.et
Invivyd Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Invivyd Shareholder Action Reminder - TMX Newsfile
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Invivyd Inc. (IVVD) Climbs 3.92% to $0.57 as Biotech Stock Nears Key Resistance LevelPositive Gamma - dars.gov.et
Invivyd grants 277,500 inducement stock options to new hires at $0.54 exercise price - Bitget
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Invivyd Inc (IVVD) Valuation: PE, PB & Fair Value Analysis - TradingKey
BlackRock (NYSE: BLK) discloses 5.5% beneficial stake in Invivyd (IVVD) - Stock Titan
Invivyd Inc (IVVD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Invivyd Inc (IVVD) Cash Flow - TradingKey
Invivyd Market Sentiment - Benzinga España
IVVD|Invivyd Inc|Price:0.604|Chg%:-0.007 - TradingKey
Invivyd Inc (IVVD) Balance Sheet - TradingKey
Invivyd Inc (IVVD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Invivyd Inc (IVVD) Income Statement - TradingKey
Invivyd Inc (IVVD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IVVD|Invivyd Inc|Price:0.659|Chg%:+0.055 - TradingKey
Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IVVD|Invivyd Inc|Price:0.611|Chg%:+0.002 - TradingKey
IVVD|Invivyd Inc|Price:0.728|Chg%:+0.041 - TradingKey
Invivyd Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Invivyd Inc (IVVD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IVVD stock trades around recent lows as Invivyd highlights COVID-19 antibody pipeline - Ad-hoc-news.de
Invivyd Inc. (IVVD) Slides 5.76% as Resistance Holds Near $0.78Moving Average Ribbon - dars.gov.et
Invivyd stock trades around recent lows as investors weigh antibody revenue outlook - Ad-hoc-news.de
Invivyd Inc. (IVVD) Q1 2026 Earnings: EPS Falls Short of Estimates; Stock Edges Up Despite Wider LossEPS Surprise History - dars.gov.et
Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK) - The Globe and Mail
Invivyd Inc updates investors on its antiviral pipeline as Nasdaq-listed biotech advances - AD HOC NEWS
H.C. Wainwright reiterates Invivyd stock rating on regulatory path - Investing.com
H.C. Wainwright reiterates Invivyd stock rating on regulatory path By Investing.com - Investing.com South Africa
Invivyd Inc. (IVVD) Surges Nearly 13% as Bulls Test Key Resistance at $0.99Protective Put - dars.gov.et
Invivyd Inc stock and Covid antibody focus - AD HOC NEWS
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allen Robert D. III | Chief Scientific Officer |
Feb 17 '26 |
Sale |
1.54 |
18,189 |
28,004 |
133,879 |
| Green Julie | Chief Human Resources Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Green Julie | Chief Human Resources Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Duke William E. | Chief Financial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Duke William E. | Chief Financial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
117,717 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
138,681 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 18 '26 |
Sale |
1.58 |
34,939 |
55,127 |
181,736 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 17 '26 |
Sale |
1.54 |
32,771 |
50,454 |
216,675 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):